Notably, EGR1 silencing inhibited pancreatic cancer cell growth and promoted apoptosis.The conclusion that EGR1 expression may affect the sensitivity of pancreatic cancer to gemcitabine provides a new solution for the clinical reduction of drug resistance in pancreatic cancer. The gene discussed is EGR1; the disease is familial pancreatic carcinoma.